Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11447494 Tricyclic amine compounds as CDK2 inhibitors

Patent 11447494 was granted and assigned to Incyte on September, 2022 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Patent Applicant

Incyte

Current Assignee

Incyte

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

114474940

Patent Inventor Names

Qinda Ye0

Liangxing Wu0

Ken Mukai0

Wenqing Yao0

Date of Patent

September 20, 2022

Patent Application Number

168635460

Date Filed

April 30, 2020

Patent Citations

‌

US Patent 10308644 Heterocyclic compounds as immunomodulators

‌

US Patent 11066404 Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors

Patent Citations Received

‌

US Patent 11981671 Bicyclic pyrazolyl amines as CDK2 inhibitors

‌

US Patent 11851426 Bicyclic amines as CDK2 inhibitors

‌

US Patent 11866432 Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors

‌

US Patent 11919904 Sulfonylamide compounds as CDK2 inhibitors

‌

US Patent 11976073 Bicyclic amines as CDK2 inhibitors

Patent Primary Examiner

CPC Code

No article content yet.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11447494 Tricyclic amine compounds as CDK2 inhibitors

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API